vs
Side-by-side financial comparison of ADC Therapeutics SA (ADCT) and FIBROGEN INC (KYNB). Click either name above to swap in a different company.
FIBROGEN INC is the larger business by last-quarter revenue ($25.4M vs $23.1M, roughly 1.1× ADC Therapeutics SA). On growth, ADC Therapeutics SA posted the faster year-over-year revenue change (36.4% vs -29.9%). Over the past eight quarters, ADC Therapeutics SA's revenue compounded faster (13.7% CAGR vs -7.8%).
ADC Telecommunications, Inc. was a communications company in Eden Prairie, Minnesota, a southwest suburb of Minneapolis. It was acquired by TE Connectivity in December 2010 and ceased to exist as a separate entity. ADC products were sold by CommScope after it acquired the Broadband Network Solutions business unit from TE Connectivity in August 2015.
FibroGen Inc. is a biopharmaceutical firm developing and commercializing innovative therapies for unmet medical needs, targeting fibrotic diseases, anemia and cancer. Its lead product roxadustat is approved in multiple markets including China and Japan, serving patients across key therapeutic segments.
ADCT vs KYNB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2024
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $25.4M |
| Net Profit | — | $-32.9M |
| Gross Margin | — | 15.9% |
| Operating Margin | -77.7% | -193.9% |
| Net Margin | — | -129.8% |
| Revenue YoY | 36.4% | -29.9% |
| Net Profit YoY | — | 57.1% |
| EPS (diluted) | $0.04 | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.1M | — | ||
| Q3 25 | $15.8M | — | ||
| Q2 25 | $18.1M | — | ||
| Q1 25 | $17.4M | — | ||
| Q4 24 | $16.9M | — | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | $17.0M | — | ||
| Q1 24 | $17.8M | $25.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-41.0M | — | ||
| Q2 25 | $-56.6M | — | ||
| Q1 25 | $-38.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-44.0M | — | ||
| Q2 24 | $-36.5M | — | ||
| Q1 24 | $-46.6M | $-32.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 15.9% |
| Q4 25 | -77.7% | — | ||
| Q3 25 | -196.6% | — | ||
| Q2 25 | -244.1% | — | ||
| Q1 25 | -163.5% | — | ||
| Q4 24 | -191.8% | — | ||
| Q3 24 | -197.4% | — | ||
| Q2 24 | -170.5% | — | ||
| Q1 24 | -188.3% | -193.9% |
| Q4 25 | — | — | ||
| Q3 25 | -260.1% | — | ||
| Q2 25 | -313.2% | — | ||
| Q1 25 | -221.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -244.1% | — | ||
| Q2 24 | -214.6% | — | ||
| Q1 24 | -261.1% | -129.8% |
| Q4 25 | $0.04 | — | ||
| Q3 25 | $-0.30 | — | ||
| Q2 25 | $-0.50 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.42 | — | ||
| Q2 24 | $-0.38 | — | ||
| Q1 24 | $-0.56 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $261.3M | $177.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-185.8M | $-228.1M |
| Total Assets | $323.1M | $365.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $261.3M | — | ||
| Q3 25 | $234.7M | — | ||
| Q2 25 | $264.6M | — | ||
| Q1 25 | $194.7M | — | ||
| Q4 24 | $250.9M | — | ||
| Q3 24 | $274.3M | — | ||
| Q2 24 | $300.1M | — | ||
| Q1 24 | $234.3M | $177.6M |
| Q4 25 | $-185.8M | — | ||
| Q3 25 | $-238.2M | — | ||
| Q2 25 | $-199.2M | — | ||
| Q1 25 | $-238.2M | — | ||
| Q4 24 | $-202.6M | — | ||
| Q3 24 | $-171.9M | — | ||
| Q2 24 | $-131.7M | — | ||
| Q1 24 | $-194.4M | $-228.1M |
| Q4 25 | $323.1M | — | ||
| Q3 25 | $289.8M | — | ||
| Q2 25 | $321.6M | — | ||
| Q1 25 | $272.5M | — | ||
| Q4 24 | $322.0M | — | ||
| Q3 24 | $349.1M | — | ||
| Q2 24 | $371.8M | — | ||
| Q1 24 | $308.0M | $365.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.1M | $-59.3M |
| Free Cash FlowOCF − Capex | — | $-59.3M |
| FCF MarginFCF / Revenue | — | -233.9% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-274.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.1M | — | ||
| Q3 25 | $-29.6M | — | ||
| Q2 25 | $-24.1M | — | ||
| Q1 25 | $-56.3M | — | ||
| Q4 24 | $-21.9M | — | ||
| Q3 24 | $-25.0M | — | ||
| Q2 24 | $-32.8M | — | ||
| Q1 24 | $-44.1M | $-59.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-56.6M | — | ||
| Q4 24 | $-21.9M | — | ||
| Q3 24 | $-25.3M | — | ||
| Q2 24 | $-32.9M | — | ||
| Q1 24 | $-44.6M | $-59.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -325.2% | — | ||
| Q4 24 | -129.8% | — | ||
| Q3 24 | -140.2% | — | ||
| Q2 24 | -193.0% | — | ||
| Q1 24 | -250.0% | -233.9% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 3.0% | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADCT
Segment breakdown not available.
KYNB
| Drug Product Revenue | $24.5M | 97% |
| Other | $878.0K | 3% |
